Autres langues AbbVie Inc.

Actions

ABBV

US00287Y1091

Produits pharmaceutiques

Marché Fermé - Nyse Autres places de cotation 22:00:03 08/05/2026			Varia. 5j.	Varia. 1 janv.
201,55 ^USD	-0,57 %		-2,44 %	-11,79 %

09/05	La réussite fiscale irlandaise face au risque de dépendance
05/05	ABBVIE INC. : Daiwa Securities toujours positif	ZM

Autres langues

09/05	Ireland's fiscal success faces the risk of over-reliance
08/05	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance
06/05	AbbVie to Present at the Bank of America Securities Healthcare Conference
06/05	Morning Meeting: Anleger sind echte Chip-Jäger
05/05	AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
05/05	AbbVie Inc. Presents New Long-Term Data For Skyrizi And Rinvoq In Inflammatory Bowel Diseases
04/05	Weight-loss revolution sparks new appetite for aesthetics firms
04/05	Global pharma companies that have publicly announced Trump drug pricing agreements
04/05	Kyverna Therapeutics, Inc. Appoints Nadia Dac as Chief Commercial Officer, Effective May 4, 2026
04/05	SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
04/05	Abbvie Announces Skyrizi (Risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
04/05	Tenax Therapeutics, Inc. Appoints Timothy Healey as Chief Commercial Officer, Effective May 4, 2026
01/05	Big Pharma M&A set for mega year as patent expiries drive deal urgency
30/04	AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
30/04	AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says
30/04	Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
30/04	MORNING BRIEFING - USA/Asien
30/04	MORNING BRIEFING - Deutschland/Europa -2-
29/04	MÄRKTE USA/Wall Street wenig verändert - Zwischen Fed-Entscheid und Tech-Zahlen
29/04	AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
29/04	MÄRKTE USA/Zurückhaltung vor Fed-Entscheid und Tech-Zahlen
29/04	AbbVie Raises 2026 Outlook Following First-Quarter Beat on Immunology Growth
29/04	AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
29/04	AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
29/04	Abbvie shares up 0.3% after Q1 results beat